



Case Report

Late presentation of secondary cycling - nitrobenzene poisoning: A rare case report

Virendra Goyal*

142, Taruchaya Nagar, Tonk Road, Jaipur, Rajasthan, India

*Corresponding author's email: virendra601@yahoo.co.in

How to cite this article: Virendra Goyal. Late presentation of secondary cycling - nitrobenzene poisoning: A rare case report. IAIM, 2014; 1(3): 39-43.

Available online at www.iaimjournal.com

Received on: 14-10-2014

Accepted on: 20-10-2014

Abstract

We presented here a case of acute nitrobenzene poisoning in which effective clinical evaluation and timely management in form of repeated intravenous methylene blue and blood transfusions played a vital role to save a life. It is very important to take care of patient who presented late after heavy exposure from the secondary cycling of nitrobenzene from body stores. Clinicians should be aware of this uncommon, but treatable and potential serious poisoning of nitrobenzene. Methemoglobinemia can lead to high mortality but effective treatment with methylene blue is preferential.

Key words

Acute methemoglobinemia, Methylene blue, Nitrobenzene poisoning, Blood transfusion.

Introduction

Nitrobenzene is also known as nitrobenzol, mirbane oil or essence of mirbane. When introduced into the body, it is metabolized by reduction to aniline. Nitrobenzene and aniline are typical aromatic nitro compounds and aromatic amino compounds that cause methemoglobinemia.

Significant methemoglobinemia due to acute nitrobenzene poisoning is uncommon and rare but life threatening emergency condition. Once poisoning is suspected on clinical evaluation, early and effective management of it may

change the outcome of a patient in positive manner.

Case report

A 30 years old, irritable, anxious male presented to emergency department who referred from other centre on mechanical ventilation with cyanosis and a greyish-brown hue. On examination, he had labored respiration of 26/min, blood pressure was 129/74 mm of Hg, pulse rate was 74/min, pupils with sluggish reaction, and SpO₂ of 89% only. There was a history of severe pain in the abdomen, nausea,



vomiting, and dizziness, which was treated on admission at primary centre. At primary centre, oral methylene blue was given (5 ml, 12 hourly), as to non-availability of intravenous therapy. An urgent ultrasonography of abdomen was done which ruled out any abdominal catastrophe and showed a generalized mild to moderate hepatic inflammation. Blood samples were drawn for arterial blood gas (ABG) analysis which had a chocolate brown color, which did not improve on exposure to 100% oxygen and showed compensated metabolic acidosis. X-ray of the chest and ECG were within normal limits while WBC and liver enzymes were markedly raised. Serum creatinine and blood urea were within normal range. Hemoglobin at admission was 9.4 gm%, which dropped down to 6.3 gm% on 9th day. Similarly serum bilirubin at admission was 2.0 mg% which was raised to 13.0 mg%. A clinical diagnosis of severe acute methemoglobinemia due to nitrobenzene poisoning was made.

100 mg of methylene blue (prepared as 1% sterile solution) was given intravenously and repeated after 12 hours. This improved patient's SpO₂ to 92% and then after intravenous vitamin K; vitamin C, 10% dextrose, anxiolytics, oral iron, and intravenous antibiotic were also given. Urine output was maintained above 100 ml/hour with proper hydration, maintaining a normal central venous pressure (CVP).

Multiple blood and blood products like fresh frozen plasma (FFP) were transfused. Patient at admission had severe hypokalemia (2.5 mEq/L), which was corrected by intravenous slow potassium infusion. Methemoglobin estimation in blood was done and it was significantly high (11.1 units as compared to normal values of 0.00 to 2.0). He was extubated at 48 hours and maintained on a continuous positive airway pressure (CPAP) mask, with arterial blood gas (ABG) analysis which showed a saturation of

93% and a PaO₂ of 112. He improved rapidly after the 10th day with SpO₂ of 90% on room air. Patient had a single episode of generalized tonic clonic seizure (GTCS) on 11th day and was epsolinised, followed by oral dilantin tablets (100 mg TDS). CT head was absolutely normal but liver enzymes were raised. He was discharged on the 14th day on oral iron, folate, ascorbic acid, and liver enzyme supplements and breathing exercises.

Discussion

Nitrobenzene is a pale yellow, oily liquid, with bitter almond odor and it is widely used as an intermediate in the production of various solvents, like paint remover. Common occupational exposure of nitrobenzene is via inhalation or through absorption of skin [1, 2]. In 1886, first report of nitrobenzene poisoning was noted [3] and then after various fatality reports were come into noticed [3, 4]. Nitrobenzene poisoning can be accidental or suicidal in manner [5]. Accidental exposure may possible in patients who are consuming well water with extremely high levels of nitrites and nitrates in it [6]. Lethal dose of it is varied from 1-10 g, as per different scholar authors [7, 8, 9]. A systematic literature review of already published articles on it does not provide any significant conclusive matter regarding fatalities and dose of ingestion [8]. Nitrobenzene poisoning is usually presented as chronic poisoning or as occupational hazard with development of methemoglobinemia [10]. The clinical features of ingestion of such poison are due to the rapid development of methemoglobinemia [7, 11], which is a condition of altered hemoglobin formation in which the iron presented within the hemoglobin is oxidized into ferric (Fe³⁺) state from the ferrous (Fe²⁺) state, resulting in the inability to transport oxygen effectively [12, 13, 14] and causes brownish discoloration of the blood and functional anemia [6]. After formation of

methemoglobin, it can be reduced enzymatically either via an adenine dinucleotide (NADH)-dependent reaction, which is catalysed by cytochrome b5 reductase, or an alternative pathway utilizing the nicotine adenine dinucleotide phosphate [15]. Certain drugs and chemicals can accelerate production of methemoglobin like antimalarial drugs such as chloroquine and primaquine; nitrites or nitrates, flutamide, inhaled nitric oxide, metoclopramide, local anesthetic agents like benzocaine; acetanilide, nitroprusside, sulfonamides, phenacetin, phenazopyridine hydrochloride, phenytoin, chlorates, probenecid etc. [16].

Normal physiological level of Methemoglobin is less than 1% of total hemoglobin [17]. At level of 10-15% of methemoglobin, person is usually asymptomatic with mild cyanotic changes. When methemoglobin level is 20-40%, headache, dyspnea, chest pain, tachypnea, and tachycardia develop [18]. At 40 – 50% level of methemoglobin, person feels confusion, lethargy, and metabolic acidosis which later on leading to coma, seizures, bradycardia, ventricular dysrhythmia, and hypertension [19]. Methemoglobin level around 70% is considered as fatal [20]. More severe symptoms are noted in patients with anemia or G6PD deficiency [4, 7]. In certain cases, leukocytosis has been reported along with relative lymphopenia [8]. Altered liver function tests, hepatosplenomegaly, and Heinz body haemolytic anaemia are other significant features [4, 21, 22]. Nitrobenzene is metabolized in the body and converted into p-nitrophenol and aminophenol and later on excreted in urine (up to 65%), and in stools (up to 15%) after five days of ingestion. Liver, stomach, blood, and brain may act as storage house and release it gradually [21].

History of chemical ingestion, characteristic bitter almond smell, persisting cyanosis on

oxygen therapy without severe cardiopulmonary disease, low arterial oxygen saturation, with normal ABG (calculated) oxygen saturation are very important for diagnosis. Methemoglobin detection can be done bedside by placing few drops of blood on white filter paper and observing for color change in which deoxyhemoglobin brighten and methemoglobin holds color [23]. Dark brown blood that fails to turn bright red on shaking, which suggests methaemoglobinaemia and this is supported by the chocolate red color of dried blood. Presence of nitrobenzene compounds may be confirmed spectrophotometrically and estimated by the butanone test of Schrenk [1], methemoglobin levels in the blood, and urinary presence of p-nitrophenol and p-aminophenol [3, 21, 24].

Plan of management is based upon the principles of decontamination along with symptomatic and supportive treatment. Methylene blue is the drug of choice (antidote) for the treatment of acquired (toxic) methaemoglobinaemia [25]. It is an exogenous cofactor, which greatly accelerates the NADPH-dependant methemoglobin reductase system and is indicated if the methemoglobin levels, which are more than 30% [7]. It is administered intravenously at 1 – 2 mg/kg (up to 50 mg dose in adults,) as a 1% solution over five minutes; with a repeat in one hour, if necessary. Methylene blue is act as an oxidant at levels of more than 7 mg/kg, and therefore, may cause methaemoglobinaemia in susceptible patients [26]. It is contraindicated in patients with G6PD deficiency, because it can lead to severe haemolysis. Ascorbic acid is an antioxidant that may also be administered in patients with methemoglobin levels of more than 30% [27]. In recent studies, N-acetylcysteine has been shown to reduce methemoglobin, but it is not yet an approved treatment for methaemoglobinaemia [27]. Exchange transfusion is indicated in severe cases [7, 27]. Hyperbaric oxygen is reserved only



for those patients who have a methemoglobin level > 50% or those who do not respond to standard treatment. Exchange transfusion is more widely and rapidly available compared to hyperbaric oxygen. Exchange transfusion involves replacement of the patient's red cells with donor cells and has been used in the treatment of various hemoglobinopathies [15].

In this case, we repeated low dose methylene blue and blood transfusions helped in tiding over the fluctuating symptoms due to the release of nitrobenzene from the body stores, without exceeding the maximum dose. Fresh blood transfusion improved the oxygen carrying capacity and haemoglobin content, improving the patient symptomatically. Oral charcoal and purgation up to five days helped to eliminate the body stores of nitrobenzene and prevented secondary deterioration in the patient. Taking care of nutrition, adequate urine output, and hepatoprotection prevented kidney and liver failure, which have been cited as late effects [3, 21]. Regular use of charcoal and purgation by peggla during hospital stay may be of some help according to some centers. Forced diuresis can lead to a rapid fall in methemoglobin levels and improved discoloration [8]. Ascorbic acid supplements are useful for follow-up management of methaemoglobinaemia [28].

Conclusion

Clinicians should be aware of this uncommon, but treatable and potential serious poisoning of nitrobenzene with secondary cycling from the body tissues. Methemoglobinemia can lead to high mortality but effective treatment with methylene blue is preferential.

Acknowledgement

The author is highly thankful to Jeevanrekha CCTH, Jaipur team for their kind cooperation and wholehearted support in.

References

1. Min JW, Park SY, Lee GR, Jeon YD, Jung JY, Cho YJ, Nam HW. Case of acute methemoglobinemia caused by nitrobenzene ingestion. *Korean J Med*, 2013; 84(3): 442–445.
2. Martinez MA, Ballesteros S, Almarza E, Sanchez de la Torre C, Bua S. Acute nitrobenzene poisoning with severe associated methemoglobinemia: Identification in whole blood by GF-FID and GC-MS. *J Anal Toxicol*, 2003; 27(4): 221–5.
3. Gupta G, Poddar B, Salaria M, Parmar V. Acute nitrobenzene poisoning. *Indian Pediatr.*, 2000; 37: 1147–8.
4. Dutta R, Dube SK, Mishra LD, Singh AP. Acute methemoglobinemia. *Internet J Emerg Intensive Care Med.*, 2008; 11: 1092–4051.
5. R. Ewert, E Buttgereit, M. PrCigel, R Reinke. Intravenous injection of India ink with suicidal intent. *Int.J. Med. LegalMed.*, 1998; 111: 91-92.
6. Michelle, Kumar M. Methemoglobinemia overview. *e medicine from web med*. Available from: <http://www.emedicine.medscape.com/article/956528-overview>. Accessed in 2010.
7. Chongtham DS, Phurailatpam, Singh MM, Singh TR. Methemoglobinemia in nitrobenzene poisoning. *J Postgrad Med.*, 1997; 43: 73–4.
8. International Program on Chemical safety (IPCS) – 2003 (8.11) Nitrobenzene. Environmental health criteria 230. Geneva: WHO. Available from: <http://www.inchem.org/documents/ehc/ehc/ehc230.htm#8.1.1;#7.8>. Accessed in 2003.
9. Harris JC, Rumack BH, Paterson RG, McGuire BM. Methaemoglobinemia

- resulting from absorption of nitrates. JAMA, 1979; 242: 2869-2871.
10. Aruna Dewan, Ashwin Patel, Habibullah Saiyed. Acute Methemoglobinemia - A Common Occupational Hazard in an Industrial City in Western India. J Occup Health, 2001; 43: 168-171.
 11. Schimelman MA, Soler JM, Muller HA. Methaemoglobinem: Nitrobenzene ingestion. J Am Coll Emerg Phys, 1978; 7: 406-408.
 12. Bradberry SM, Aw TC, Williams NR, Vale JA. Occupational methemoglobinaemia. Occup Environ Med, 2001; 58(9): 611-616.
 13. Park SS, Nam EM, Kim IH, Kim JS, Lim YJ, Ahn SJ. A case of methemoglobinemia caused by hair dyeing with henna. Korean J Med, 2007; 72(2): 314-317.
 14. Shin JH, Lee JK, Park SS, Na SJ, Park JS. Indoxacarb pesticide poisoning with methemoglobinemia. J Korean Soc Clin Toxicol, 2006; 4(2): 158-160.
 15. Michael A. Pritchett, Nathalie Celestin, Nicole Tilluckdharry, Katherine Hendra, Peter Lee. Successful Treatment of refractory methemoglobinemia with red blood cell exchange transfusion. Chest Meeting Abstracts, 2006; 130(4): 294.
 16. Ferraro-Borgida MJ, Mulhern SA, DeMeo MO, Bayer MJ. Methemoglobinemia from perineal application of an anesthetic cream. Ann Emerg Med, 1996; 27: 785-8.
 17. Mansouri A. Review: Methaemoglobinemia. Am J Med Sci, 1985; 29: 200-209.
 18. Walley T, Flangan M. Nitrite-induced methaemoglobinemia. Postgrad Med J, 1987; 63: 643-644.
 19. Piotrowski. Further investigations on the evaluation of exposure to nitrobenzene. Br. J. Ind. Med., 1967; 24: 60-67.
 20. Eisen Kraft JB. Pulse oximeter desaturation due to methaemoglobinemia. Anaesthesiology, 1988; 68: 279-282.
 21. Wakefield JC. Nitrobenzene toxicological overview file format. Available form: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1222068850334 page 1-10. Accessed in 2008.
 22. David C Lee. Methemoglobinemia. eMedicine from web med. Accessed in 2012.
 23. Mary Denshaw-Burke, John Schofstell. Methemoglobinemia. eMedicine from web med. Accessed in 2012.
 24. Verive M, Kumar M. Methemoglobinemia: Differential diagnoses and workup, e medicine from web med. Available from: <http://www.emedicine.medscape.com/article/956528-diagnosis>. Accessed in 2010.
 25. Curry S. Methaemoglobinemia. Ann Emerg Med, 1982; 11: 214-221.
 26. Whitwan JG, Taylor AR, White JM. Potential hazard of methylene blue. Anaesthesia, 1979; 34: 181-182.
 27. Verive M, Kumar M. Methemoglobinemia: Treatment and Medication, e medicine from web med. Available from: <http://www.emedicine.medscape.com/article/956528-treatment>. Accessed in 2010.
 28. Kaushik P, Zuckerman SJ, Campo NJ, Banda VR, Hayes SD, Kaushik R. Celecoxib Induced Methemoglobinemia. Ann Pharmacother., 2004; 38: 1635-8.

Source of support: Nil

Conflict of interest: None declared.